Class II senolytics inhibit survival pathways elicited by senescent Download Scientific Diagram Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols
product description
Why choose thelockerguy wholesale?
Show More
foxo4-dri senolytic human trial The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI